Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Union Budget
Budget 2011-2012 Home
Industry Expectations - Budget 2011-2012
Industry Reactions - Budget 2011-2012
Budget 2010-2011
Budget 2010-2011 Home
Industry Expectations - Budget 2010-2011
Industry Reactions - Budget 2010-2011
Contributor's Corner
Bonanza Portfolio
Hemant K Gupta
Krish Bhatt
S A A R T H I
Trinity Investments
Exchange Information
BSE 2009 Holidays
NSE 2009 Holidays
Investor Guide
Depository & Dematerialisation
Grievance Redressal
Investor Guide
SEBI
Trading of Securities
Transfer of Securities
Your Rights
Budget 2009-2010
Budget 2009-2010 Home
Industry Expectations - Budget 2009-2010
Industry Reactions - Budget 2009-2010
Interim Budget 2009-2010 Home
Industry Expectations - Interim Budget 2009
Budget 2008-2009
Railway Budget 2008-2009
Industry Expectations - Budget 2008
Union Budget 2008-2009
Highlights of Budget 2008-2009
Summary of Budget 2008-2009
Industry Reactions - Budget 2008
IPOs
Current IPOs
Past IPOs
IPO Subscription
Mutual Funds
Gold Exchange Traded Fund
MF Unique Holding
Forthcoming Dividends
ELSS Schemes Comparison
Tax Plans
New Fund Offers
Research
Arbitrages
Equity
Market Whispers
Tax Planning
Home
Equity Linked Savings Scheme
Post Office MIS
9% GOI Senior Citizens Savings Scheme
8% Savings (Taxable) Bonds
Kisan Vikas Patra
National Savings Certificate
Public Provident Fund
Research

| More

Crisil - Panacea Biotec Ltd - Independent Equity Research Report

Posted On: 2011-12-14 22:00:23

Panacea Biotec Ltd (Panacea) has so far witnessed strong business momentum in both combination vaccines and formulations. While demand continues to gain traction, Panacea's growth will likely hit a roadblock as WHO (World Health Organisation) has de-listed its combination vaccines, including the high-margin EasyFive, from the pre-qualified list of vaccines. We have lowered our FY12 estimates to account for the loss in business. However, we maintain our fundamental grade of 3/5 as we believe that the problem is likely to be a short term one and the long-term business prospects look optimistic. Growth momentum in combination vaccines stalled in the near term.

Combination vaccines had been witnessing strong traction in demand, apparent from EasyFive's ~220% y-o-y revenue growth in FY11. WHO has recently delisted the product because of quality management issues. Consequently, we expect growth to get stalled as UNICEF is the largest customer. However, management is expecting to fix the issue in 3-4 months. We expect the supplies to resume by Q1FY13 and remain optimistic on the long-term growth prospects of combination vaccines.

Expect gradual de-growth in polio vaccine sales

Polio vaccine sales declined by ~17% y-o-y in FY11 largely due to: 1) decline in procurement by UNICEF because of increase in polio eradication globally, and 2) Indian government now procuring vaccines on need basis only. However, we view limited near-term risk to demand for polio vaccines given the significant number of cases still recorded globally. Going ahead, we expect sales to de-grow, but on a more gradual curve.

New products and geographic expansion to benefit formulations

Formulation sales grew ~24% y-o-y in FY11, largely driven by strong traction in its existing products and entries into new markets. Exports grew by ~110% driven by strong demand for Tacrolimus and Cyclosporine in Latin America. Going ahead, we believe that catalysts such as expected approval in regulated markets and launch of new products will continue to crank the growth engine.

Revenue growth and profitability curve to cave-in in FY12

We expect FY12 revenue to decline ~25% y-o-y to ~Rs 8,650 mn and EBITDA margin to contract by 1,440 bps to ~8% on loss of EasyFive sales to UNICEF and higher raw material costs driven by unfavourable forex movement. We expect revenue and margins to improve to ~Rs 11,934 mn and 19.0% in FY13.

Valuations the current price has 'upside'

Based on our new estimates, we arrive at a fair value of Rs 100 per share. We propose a valuation grade of 4/5, indicating that the market price has upside from the current levels.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com


Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.





Other Headlines:

Anand Rathi recommends BUY on Jyothy Laboratories
Albert David - Prescription for Gain - Sunidhi
PTC India Ltd - Q2FY15 Update - CMP Rs.98, Rating changed to Hold with revised Target of Rs.102 - Sushil Finance
IndusInd Bank Ltd - Q2FY15 Result First-Cut - Microsec
RIL - First cut Q2FY15 - Microsec
Federal Bank Ltd - Initiating Coverage, CMP Rs.122, BUY, Target Rs.156 - Sushil Finance
Select PSU Banks may witness renewed buying - Microsec
Dolphin Offshore Enterprises - Edging Forward At Sea - Nirmal Bang
Sun Pharmaceutical Industries - Surprise Audit Of Halol Unit By USFDA - Outcome Is Key - Nirmal Bang
Triveni Turbine - Management Meet Update - Nirmal Bang
Steel Sector - Iron Ore Prices Tumble, Expansion In Margins Likely - Nirmal Bang
SBI - Calibrated Growth Likely - Nirmal Bang
Adi Finechem - A Quantum Leap - Nirmal Bang
Citi: Three stocks to play India's logistics sector
Alicon Castalloy Ltd. - Q1 FY15 Result Quick View - CMP Rs.146 - Maintain BUY - INVESt VISTa
CRISIL Research unveils equity research report of Nandan Denim Ltd
Narendra Properties Fixes Book Closure for 19th AGM
Surana Industries Ltd posts Q1 loss of Rs. 10.80 crores
Ricoh India - Stock Review - Sushil Finance
Minda Industries Ltd - Q4 FY14 Result - Quick View - CMP Rs.277, Maintain BUY - Sushil Finance
Road Ministry approves over Rs. 40,000 crore highway projects - Angel Broking
UPL - 50% stake sale in the Brazilian Agrochemical company - Angel Broking
UPL - stake sale in Brazilian company - Angel Broking
Cipla in US $14mn deal with Sri Lankan distributor firm - Angel Broking
Triveni Turbine Ltd - Q4 & FY14 Result - Quick View - CMP Rs.95, Maintain HOLD - Sushil Finance
City Union Bank Ltd. - Q4FY14 Update, CMP Rs.71, Rating Changed to HOLD with revised Target of Rs.72 - Sushil Finance
Vishal Sikka will take over as CEO and MD of Infosys - Angel Broking
Views on State Bank of India 4QFY2014 results - Angel Broking
Views on Ashok Leyland 4QFY2014 results - Angel Broking
Views on Motherson Sumi Systems 4QFY2014 results - Angel Broking
Views on Ramco Cements 4QFY2014 results - Angel Broking
Views on UCO Bank 4QFY2014 results - Angel Broking
USFDA letter to Sun Pharma's response on the import alert on its karkhadi plant - Angel Broking
Views On Cadila Healthcare results - Angel Broking
Views on Apollo Tyres results - Angel Broking
Views on Jammu and Kashmir Bank - Angel Broking
Views on Bank Of India results - Angel Broking
Views on Bajaj Auto 4QFY2014 results - Angel Broking
Views on Sun Pharma announces settlement of litigation for generic Gleevec in US - Angel Broking
Alicon Castalloy Ltd. - Q4 FY14 Result Update - CMP Rs.131 - Rating Changed to BUY for increased target of Rs.189 - Sushil Finance
Petronet LNG Ltd - Q4FY14 Update-CMP Rs.145, Rating Changed to HOLD, Target increased to Rs.152 - Sushil Finance
European regulator lifts drug export ban from Ranbaxy Laboratories' Toansa plant - Angel Broking
Angel Broking recommends Neutral on Aurobindo Pharma - 4QFY2014 Result Update
Angel Broking recommends Buy on Bajaj Electricals with a Target Price of Rs. 441
Angel Broking recommends Buy on Dishman Pharmaceuticals with a Target Price of Rs. 123
Atul Auto Ltd. - Q4 FY14 Result Update - CMP Rs.384 - Rating Changed To Buy For Increased Target of Rs.469- INVESt VISTa
Angel Broking recommends Accumulate on Ipca Labs with a Target Price of Rs. 882
Angel Broking recommends Buy on Sun Pharma with a Target Price of Rs. 706
Angel Broking recommends Buy on Cipla with a Target Price of Rs. 431
Angel Broking recommends Buy on Siyaram Silk Mills with a Target Price of Rs. 602


  
Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2014